Edinburgh Research Explorer

Tetrazine-mediated bioorthogonal prodrug–prodrug activation

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Accepted author manuscript, 644 KB, PDF document

    Licence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

  • Download as Adobe PDF

    Final published version, 669 KB, PDF document

    Licence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

http://xlink.rsc.org/?DOI=C8SC02610F
Original languageEnglish
Pages (from-to)7198-7203
JournalChemical Science
Volume9
Issue number36
Early online date12 Jul 2018
DOIs
Publication statusE-pub ahead of print - 12 Jul 2018

Abstract

The selective and biocompatible activation of prodrugs within complex biological systems remains a key challenge in medical chemistry and chemical biology. Herein we report, for the first time, a dual prodrug activation strategy that fully satisfies the principle of bioorthogonality by the symbiotic formation of two active drugs without the generation of any by-products. This dual and traceless prodrug activation strategy takes advantage of the INVDA chemistry of tetrazines (here a prodrug), generating a pyridazine-based miR21 inhibitor and the anti-cancer drug camptothecin, and offers a new concept in prodrug activation.

Download statistics

No data available

ID: 75479740